Advertisement

Perioperative Bridging Therapy With Unfractionated Heparin or Low-Molecular-Weight Heparin in Patients With Mechanical Prosthetic Heart Valves on Long-Term Oral Anticoagulants (from the REGIMEN Registry)

      Patients with mechanical prosthetic heart valves require long-term oral anticoagulant therapy (OAT). During the temporary interruption of OAT, bridging anticoagulant therapy with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) is recommended. This prespecified subgroup analysis from REGIMEN—a large, prospective, multicenter registry—compared UFH (n = 73) and LMWH (n = 172) as bridging anticoagulation in patients with mechanical heart valves on long-term OAT. Patient demographics and co-morbidities were generally similar between groups. There were more bileaflet valves in the LMWH group (67.4% vs 43.8%, p = 0.0005), but no differences in valve positions between groups. The LMWH group was less likely to undergo major surgery (33.7% vs 58.9%, p = 0.0002) and cardiothoracic surgery (7.6% vs 19.2%, p = 0.008), and to receive intraprocedural anticoagulants or thrombolytics (4.1% vs 13.7%, p = 0.007). Major adverse event rates (5.5% vs 10.3%, p = 0.23) and major bleeds (4.2% vs 8.8%, p = 0.17) were similar in the LMWH and UFH groups, respectively; 1 arterial thromboembolic event occurred in each group. More LMWH-bridged patients were treated as outpatients or discharged from the hospital in <24 hours (68.6% vs 6.8%, p <0.0001). Multivariate logistic analysis found no significant differences in major bleeds and major composite adverse events when adjusting for cardiothoracic or major surgery between groups. In conclusion, for patients with mechanical prosthetic heart valves on long-term OAT, mostly outpatient-based LMWH bridging therapy appears to be feasible for selected procedures, is as safe as UFH, and is associated with a low arterial thromboembolic rate.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Spyropoulos A.C.
        • Jenkins P.
        • Bornikova L.
        A disease management protocol for outpatient perioperative bridge therapy with enoxaparin in patients requiring temporary interruption of long-term oral anticoagulation.
        Pharmacotherapy. 2004; 24: 649-658
        • Spandorfer J.M.
        • Lynch S.
        • Weitz H.H.
        • Fertel S.
        • Merli G.J.
        Use of enoxaparin for the chronically anticoagulated patient before and after procedures.
        Am J Cardiol. 1999; 84 (A10.): 478-480
        • Tinmouth A.H.
        • Morrow B.H.
        • Cruickshank M.K.
        • Moore P.M.
        • Kovacs M.J.
        Dalteparin as periprocedure anticoagulation for patients in warfarin and at high risk of thrombosis.
        Ann Pharmacother. 2001; 35: 669-674
        • Ferreira I.
        • Dos L.
        • Tornos P.
        • Nicolau I.
        • Permanyer-Miralda G.
        • Soler-Soler J.
        Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol.
        Heart. 2003; 89: 527-530
      1. Anticoagulation in Prosthetic Heart Valves and Pregnancy Consensus Report (APPCR)Anticoagulation and enoxaparin use in patients with prosthetic heart valves and/or pregnancy.
        Clin Cardiol Consens Rep. 2002; 3: 1-20
        • Spyropoulos A.C.
        • Turpie A.G.
        • Dunn A.S.
        • Spandorfer J.
        • Douketis J.
        • Jacobson A.
        • Frost F.J.
        • REGIMEN Investigators
        Clinical outcomes with unfractionated heparin or low-molecularweight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.
        J Thromb Haemost. 2006; 4: 1246-1252
        • Nicolaides A.N.
        • Breddin H.K.
        • Fareed J.
        • Goldhaber S.
        • Haas S.
        • Hull R.
        • Kalodiki E.
        • Myers K.
        • Samama M.
        • Sasahara A.
        • Cardiovascular Disease Educational and Research Trust and the International Union of Angiology
        Prevention of venous thromboembolism.
        Int Angiol. 2001; 20: 1-37
        • Charlson M.
        • Szatrowski T.P.
        • Peterson J.
        • Gold J.
        Validation of a combined comorbidity index.
        J Clin Epidemiol. 1994; 47: 1245-1251
        • Beyth R.J.
        • Quinn L.M.
        • Landefeld C.S.
        Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.
        Am J Med. 1998; 105: 91-99
        • Katholi R.E.
        • Nolan S.P.
        • McGuire L.B.
        The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves: a prospective study.
        Am Heart J. 1978; 96: 163-165
        • Halbritter K.M.
        • Wawer A.
        • Beyer J.
        • Oettler W.
        • Schellong S.M.
        Bridging anticoagulation for patients on long-term vitamin-K-antagonists: a prospective 1 year registry of 311 episodes.
        J Thromb Haemost. 2005; 3: 2823-2825
        • Spyropoulos A.C.
        • Frost F.J.
        • Hurley J.S.
        • Roberts M.
        Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy.
        Chest. 2004; 125: 1642-1650
        • Montalescot G.
        • Polle V.
        • Collet J.P.
        • Leprince P.
        • Bellanger A.
        • Gandjbakhch I.
        • Thomas D.
        Low molecular weight heparin after mechanical heart valve replacement.
        Circulation. 2000; 101: 1083-1086
        • Douketis J.D.
        • Berger P.B.
        • Dunn A.S.
        • Jafer A.K.
        • Spyropoulos A.C.
        • Becker R.C.
        • Ansell J.
        The perioperative management of antithrombotic therapy.
        Chest. 2008; 133: 299S-340S
        • Kovacs M.J.
        • Kearon C.
        • Rodger M.
        • Anderson D.R.
        • Turpie A.G.
        • Bates S.M.
        • Desjardins L.
        • Douketis J.
        • Kahn S.R.
        • Solymoss S.
        • Wells P.S.
        Single-arm study of bridging therapy with 15 low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.
        Circulation. 2004; 110: 1658-1663
        • Douketis J.D.
        • Johnson J.A.
        • Turpie A.G.
        Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
        Arch Intern Med. 2004; 164: 1319-1326
        • Baudo F.
        • de Cataldo F.
        • Mostarda G.
        • Ghirarduzzi A.
        • Molinatti M.
        • Pengo V.
        • Poli D.
        • Tosetto A.
        • Tiraferri E.
        • Morra E.
        Management of patients on long-term oral anticoagulant therapy undergoing elective surgery: survey of the clinical practice in the Italian anticoagulation clinics.
        Intern Emerg Med. 2007; 2: 280-284
        • Hammerstingl C.
        • Tripp C.
        • Schmidt H.
        • von der Recke G.
        • Omran H.
        Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry.
        J Heart Valve Dis. 2007; 16: 285-292
        • Jaffer A.K.
        • Ahmed M.
        • Brotman D.J.
        • Bragg L.
        • Seshadri N.
        • Qadeer M.A.
        • Klein A.
        Low molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.
        J Thromb Thrombolysis. 2005; 20: 11-16
        • Constans M.
        • Santamaria A.
        • Mateo J.
        • Pujol N.
        • Souto J.C.
        • Fontcuberta J.
        Low-molecularweight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy.
        Int J Clin Pract. 2007; 61: 212-217
        • Spyropoulos A.C.
        • Turpie A.G.
        Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation.
        Curr Opin Pulm Med. 2005; 11: 373-379